Position in ANRO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,765,129
+$367,473 QoQ
Shares Held
78,520
0.0% QoQ
Ownership
0.200%
of shares outstanding
% of Portfolio
0.43%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANRO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Almitas Capital LLC holds $38,543,506 across 6 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DSGN |
Design Therapeutics, Inc.
|
1,026,893 | $14,859,141 | |
| 2 | LYEL |
Lyell Immunopharma, Inc.
|
581,407 | $8,168,768 | |
| 3 | ANTX |
AN2 Therapeutics, Inc.
|
1,469,129 | $7,110,584 | |
| 4 | ALXO |
Alx Oncology Holdings Inc
|
2,938,431 | $6,082,552 | |
| 5 | RLYB |
Rallybio Corp
|
120,682 | $1,930,912 | |
| 6 | CABA |
Cabaletta Bio, Inc.
|
125,900 | $391,549 |
All Filings in ANRO
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,765,129 | 78,520 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,397,656 | 78,520 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $784,482 | 195,145 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $429,319 | 195,145 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $506,273 | 234,386 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $1,129,037 | 266,912 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||